Related Experiment Video
Updated: Sep 16, 2025

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
Published on: November 29, 2024
Artificial Sweeteners and Cardiovascular Risk in Hungary: Beyond Traditional Risk Factors
Battamir Ulambayar1, Attila Csaba Nagy1,2
1Department of Health Informatics, Faculty of Health Sciences, University of Debrecen, 4032 Debrecen, Hungary.
Abstract:
Background/Objectives: Cardiovascular disease (CVD) remains a leading cause of mortality in Hungary, with rising obesity and diabetes rates exacerbating the burden. Artificial sweeteners, promoted as healthier alternatives to sugar, have been linked to CVD risk in other populations, but evidence in Hungary is limited. This study aims to investigate the association between artificial sweetener use and CVD prevalence in a Hungarian population, independent of traditional risk factors, using data from the 2019 European Health Interview Survey (EHIS). Methods: This cross-sectional study analyzed EHIS data (n = 5603), categorizing participants by self-reported CVD diagnoses (hypertension, coronary artery disease, myocardial infarction, or stroke). Variables included artificial sweetener use, age, sex, education, income, smoking, alcohol consumption, physical activity, diabetes, and body mass index (BMI). Chi-square tests and multivariate logistic regression, adjusted for sampling weights, were employed to assess associations. Results: Of 5603 participants, 38.7% had CVD and 16.4% used artificial sweeteners. Older age, female sex, lower education, long-term smoking cessation, obesity, diabetes, and physical inactivity increased CVD risk, while moderate alcohol consumption and sports were protective. Artificial sweetener use was significantly associated with higher CVD prevalence (OR: 1.21, 95% CI: 1.01-1.46, p = 0.01), independent of other risk factors. Conclusions: Artificial sweetener use is associated with increased CVD risk in Hungary, suggesting a need for further research and public health strategies to address this potential risk.
More Related Videos
08:21Author Spotlight: A Pharmacodissection Approach to Uncover Mechanisms in Cardiovascular Disease Risk Populations
Published on: July 21, 2023
05:58Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model
Published on: April 18, 2025
Related Concept Videos
Coronary Artery Disease I: Introduction
Oral Hypoglycemic Agents: Biguanides and Glitazones
Coronary Artery Disease IV: Preventive Measures
Hypertension III: Clinical Manifestations and Diagnostic Studies
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are...
Glucose Transporters
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes: